ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Tumor-associated macrophages and platelets in tumor microenvironment and its potential therapeutic role in ovarian cancer.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Spatial and single-cell profiling identify NDRG1⁺ macrophages as key hallmark of angiogenic remodeling and platinum resistance in HGSOC.Translational oncology · 2026Article
- Single cell transcriptomic analysis reveals molecular mechanisms of chemoresistance and immune microenvironment remodeling in ovarian cancer.Discover oncology · 2025Article
- Advance in therapies targeting tumor-associated macrophages in ovarian cancer.Frontiers in immunology · 2025Review
- Immunometabolic crosstalk between tumor- associated macrophages and ferroptotic cancer cells: mechanisms, regulation, and therapeutic applications.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ovarian cancer is one of the most lethal cancers among gynecological tumors, with most cases diagnosed at an advanced stage. Despite advancements in medical science, current therapeutic options remain somewhat constrained, leading to a persistently high mortality among patients. The tumor microenvironment (TME) critically drives ovarian cancer progression by orchestrating tumorigenesis, metastasis, and chemoresistance via intercellular crosstalk, metabolic reprogramming, and immunosuppression. Tumor-associated macrophages (TAMs) and platelets are pivotal components of the ovarian cancer immune microenvironment. These components facilitate critical oncogenic processes, including tumor cell dissemination, immune evasion, and chemoresistance. Both TAMs and platelets have emerged as promising therapeutic targets. Furthermore, bidirectional crosstalk between platelets and TAMs dynamically shapes the immunosuppressive TME. This review synthesizes the roles and mechanisms of TAMs and platelets in ovarian cancer progression, discusses emerging therapeutic strategies targeting these components, and establishes a framework for advancing novel therapies in ovarian cancer treatment.
Indexed as
Identifiers
40622485What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.